ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer
ICER report finds EGFR inhibitors are cost-effective in first-line non-small cell lung cancer, but PD-1/L1 inhibitors from Bristol, Merck and Roche may fall short in second-line treatment.
You may also be interested in...
PARP inhibitors from Tesaro, Clovis, and AstraZeneca have been tentatively chosen for the evaluation.
Drug companies are accusing the US Institute for Clinical and Economic Review of approaching cost effectiveness assessments in the same way as the UK National Health Service gatekeeper, the National Institute for Health and Care Excellence.
The Institute for Clinical & Economic Review is setting an appropriately broad scope in its review of the abuse-deterrent opioid class. But the project opens up a much larger question of how broadly to define value – and how to weigh non-economic values – in cost-effectiveness reviews.